In vitro and rat studies identified small molecule,
selective TRKA inhibitors that could help treat pain. In a high throughput
screen, four TRKA inhibitors from different molecular classes showed at least
50-fold selectivity over a nonselective receptor
tyrosine kinase (RTK).
In a rat model of inflammatory pain, one of the inhibitors reversed allodynia
with comparable potency to the NSAID naproxen.
In a rat model of neuropathic pain, the inhibitor reversed mechanical
hypersensitivity with comparable potency to Lyrica
pregabalin.
Next steps could include testing the inhibitor in additional pain models and
testing its safety profile.Pfizer
Inc. markets Lyrica for multiple indications including
pain.Creabilis S.A. has CT327,
a topical TRKA inhibitor, in Phase II testing for dermatitis and psoriasis.Nerviano Medical Sciences s.r.l.
has milciclib
maleate, an inhibitor of TRKA and cyclin
dependent kinases (CDKs),
in Phase II testing to treat cancer.
At least four other companies have TRKA inhibitors in Phase I/II or earlier
development for various diseases.

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD